The team are delighted to have been award the Best Poster in Developmental Immunotherapy at this year's ESMO conference.
We showed that early data from our Phase 1/2 study of our first-in-class ERAP1 inhibitor (GRWD5769) in patients with advanced solid tumours is looking very promising:
◼ Well-tolerated profile: GRWD5769, both as monotherapy and in combination with cemiplimab, was well tolerated with no new safety signals.
◼ Proof of mechanism: Immunopeptidomics shows that ERAP1 inhibition drives changes in the displayed immunopeptidome in a dose dependent manner, and that leads to diversification and remodeling of the T-cell repertoire, an important step in reawakening immune responses to tumours.
◼ Encouraging clinical signals: In heavily pre-treated patients, we’ve already seen confirmed partial responses (including in MSS colorectal cancer, a notoriously immune-resistant disease) and durable disease control beyond 6 months in multiple patients.
Our presentation highlighted robust increases in TCR repertoire diversity and clear immune activation signatures following GRWD5769–induced modulation of the antigenic landscape, including data from a microsatellite stable colorectal cancer (MSS-CRC) patient who achieved a durable partial response.
We are grateful to the judges for recognizing the significance of this work. We look forward to presenting clinical response data from our expansion cohorts, including patients with resistance to anti–PD-1 therapy, in the near future.
